Navigation Links
Insulin could be Alzheimer's therapy
Date:4/1/2011

BUFFALO, N.Y. -- A low dose of insulin has been found to suppress the expression in the blood of four precursor proteins involved in the pathogenesis of Alzheimer's disease, according to new clinical research by University at Buffalo endocrinologists. The research, published in March online in the Journal of Clinical Endocrinology and Metabolism, suggests that insulin could have a powerful, new role to play in fighting Alzheimer's disease.

"Our results show clearly that insulin has the potential to be developed as a therapeutic agent for Alzheimer's, for which no satisfactory treatment is currently available," says Paresh Dandona, MD, PhD, UB distinguished professor of medicine in the School of Medicine and Biomedical Sciences and senior author on the study.

One of the four proteins shown in the study to be suppressed by insulin is a precursor to beta amyloid, the main component of plaques considered the hallmark of Alzheimer's disease.

The findings also demonstrate for the first time that the four precursor proteins studied are expressed in peripheral mononuclear cells, white blood cells that are an important component of the immune system.

The paper builds on the UB researchers' earlier work showing that insulin has a potent and rapid anti-inflammatory effect on peripheral mononuclear cells. It also builds on the well-known association between obesity, type 2 diabetes and chronic low-grade inflammation, as well as insulin resistance, all conditions that manifest a significantly increased prevalence of Alzheimer's disease.

In the study, 10 obese, type 2 diabetic patients were infused with two 100 ml units of insulin per hour over a period of four hours. The patients were all taking oral drugs to treat their diabetes; none of them were taking insulin or any antioxidant or nonsteroidal anti-inflammatory drugs. The control group received 5 percent dextrose per hour or normal saline solution.

The low-dose insulin was found to suppress the expression of amyloid precursor protein, from which beta amyloid is derived. It also suppressed presenilin-1 and presenilin-2, the two subunits of an enzyme that converts amyloid precursor protein into beta amyloid, which forms the amyloid plaques. Insulin also suppressed glycogen synthase kinase, which phosphorylates, or adds on another phosphate group, to another neuronal protein, tau, to form the neurofibrillary tangles, the other important component of Alzheimer's disease in the brain.

"Our data show, for the first time, that the peripheral mononuclear cells express some of the key proteins involved in the pathogenesis of Alzheimer's disease," says Dandona. "They demonstrate that these cells can be used for investigating the effect of potential Alzheimer's disease therapies on key proteins involved in the disease.

"Even more importantly, it is likely that insulin has a direct cellular effect on these precursor proteins while also exerting its other anti-inflammatory actions," he continues. "If this effect of insulin proves, in larger studies, to be systemic, then insulin may well be a potential therapeutic agent in treating Alzheimer's disease. The challenge is to deliver insulin directly into the brain, thus avoiding its hypoglycemic effect." Fortunately, Dandona says, a previous preliminary study has shown that intranasal delivery of insulin can lead to its entry into the brain along the olfactory nerves and that its administration may improve cognitive function in patients with Alzheimer's disease. However, he cautions, the mode of action is not known.

"Our study provides a potential rational mechanism," he says.


'/>"/>

Contact: Ellen Goldbaum
goldbaum@buffalo.edu
716-645-4605
University at Buffalo
Source:Eurekalert  

Related medicine news :

1. Hormone Outperforms Insulin in Diabetic Mice
2. Experts call for further research into the relationship between insulin therapy and cancer
3. More Info Needed on Problems With Insulin Pumps
4. New Inhaled Insulin Shows Promise for Diabetes
5. Jekyll and Hyde Factor May Control Insulin Function
6. Study Finds That Insulin-Producing Beta Cells Can Be Reborn
7. One Sleepless Night Ups Insulin Resistance
8. Mayo-led research team develop agents that keep insulin working longer
9. New pathway to cheap insulin
10. Nicer than needles: Insulin pills for diabetes finally in clinical trials
11. Diabetic potential to create own insulin
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Insulin could be Alzheimer's therapy
(Date:5/4/2016)... ... May 04, 2016 , ... World Patent Marketing , ... a sports invention that aids in the improvement of the grip and swing ... $9 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
(Date:5/4/2016)... ... 04, 2016 , ... Trinity Health today launched its inaugural ... aimed at improving care and reducing readmission rates for patients who are dually ... Health is to drive innovation that transforms our ministry and our industry to ...
(Date:5/4/2016)... ... 2016 , ... NCPDP announced today highlights from ... Frank Luntz, sharing a dynamic, bi-partisan environmental scan of healthcare-related campaign issues. Today’s ... model solution to help stem the tide of the opioid epidemic and put ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... Level ... -- announced her verbal commitment to the University of Arizona for the fall of ... announced her decision last month. Brovedani’s commitment to the GymCats came from her connection ...
(Date:5/4/2016)... ... May 04, 2016 , ... IsoComforter, Inc., ... introduction of the innovative newly improved Iso-Hip Wrap. The newly designed hip ... design enhances comfort and enables the patient to enjoy the benefits of cold ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... May 3, 2016  Forté Elements, LLC (Forté) is excited to announce the launch ... address the nutritional needs of recovery for a variety of clinical conditions. Founded in ... Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... 2016  Deerfield announced today it led the ... Inc. Graybug Vision is an early stage pharmaceutical ... care for ocular diseases including wet age-related macular ... first developed at Johns Hopkins University and has ... Graybug Vision is developing ophthalmology products ...
Breaking Medicine Technology: